bortezomib + cyclophosphamide + cytarabine + fludarabine + rituximab

This is a multi-agent chemotherapy regimen composed of five drugs—bortezomib, cyclophosphamide, cytarabine, fludarabine, and rituximab—used in the treatment of hematologic malignancies. Each component has a distinct mechanism of action: - **Bortezomib** is a proteasome inhibitor that disrupts protein degradation pathways in cancer cells, leading to apoptosis. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands and inhibits cell division. - **Cytarabine** is an antimetabolite that interferes with DNA synthesis during the S-phase of the cell cycle. - **Fludarabine** is a purine analog that inhibits DNA polymerase and ribonucleotide reductase, impairing DNA synthesis and repair. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, resulting in immune-mediated cell lysis. This combination targets malignant B-cells through multiple mechanisms including direct cytotoxicity (chemotherapy), inhibition of cellular proliferation (antimetabolites), disruption of protein homeostasis (proteasome inhibition), and immunotherapy (anti-CD20 antibody). While combinations such as bortezomib with fludarabine plus cyclophosphamide or regimens like FCR (fludarabine/cyclophosphamide/rituximab) are established for mantle cell lymphoma or chronic lymphocytic leukemia[1][4], the specific five-drug combination listed here represents an intensive regimen likely reserved for relapsed/refractory or high-risk cases where multi-modal attack on malignant cells may be warranted.